🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHepatic steatosis grading on ultrasound — what worked for you?

Hepatic steatosis grading on ultrasound — what worked for you?

marcus_mpls Sun, Oct 12, 2025 at 12:06 AM 9 replies 1,276 viewsPage 1 of 2
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Oct 12, 2025 at 12:06 AM#1

ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

The narrow version of the question is whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is.

I would rather have one careful answer than five confident ones.

21 16bbq_ray_KC, oliver_london, tane_welly and 18 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Oct 12, 2025 at 12:20 AM#2
marcus_mpls said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
20 15PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 17 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Oct 12, 2025 at 12:34 AM#3
Dr.ObesityMed said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD). After 9 months on GLP-1 therapy:

MarkerBaselineCurrentNormal Range
ALT78257-56 U/L
AST512710-40 U/L
GGT68319-48 U/L
ALP987544-147 U/L

FibroScan also improved — liver stiffness from 8.5 kPa to 6.2 kPa. The evidence for GLP-1 agonists in NAFLD/NASH is very promising.

19 14LondonLisa, mike_nyc, VendorMark and 16 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
GraceAZ_72
Member
156
678
Jan 2025
Tucson, AZ
Oct 12, 2025 at 12:48 AM#4
marcus_mpls said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

This is my experience too, for whatever a second data point is worth.

18 13JenPlateau, SallyK_inj, CryptoCarl and 15 others
Reply Quote Save Share Report
chris_chi24
Member
389
1,678
Sep 2024
Chicago, IL
Oct 12, 2025 at 1:59 AM#5

Clinical perspective, offered as context rather than as advice.

Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 318 dB/m (moderate steatosis) and stiffness 8.8 kPa (possible fibrosis). Diagnosed with NAFLD.

After 10 months: CAP dropped to 231 dB/m (minimal steatosis) and stiffness normalized to 5.3999999999999995 kPa. Hepatologist says the liver is essentially healing itself as the metabolic stress resolves.

GLP-1 agonists may become first-line NASH therapy. The Phase 3 data on semaglutide for NASH is very promising.

17 12SleepFixSam, PurityPaulOR, MaxMetOK and 14 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register